Immunosuppression: Clinical Trials

10 trials for Immunosuppression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 10
Phase 12Completed 2

Follow Immunosuppression: new trials by email Literature Review of Immunosuppression trials Research Report on Immunosuppression

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
NVX-CoV2372 - Immunosuppression, COVID-19
Phase 2CompletedUniversity of Wisconsin, Madison212023-11-202025-10-20
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Thymoglobulin, Fludarabine, Cyclophosphamide - Severe Aplastic Anemia, Aplastic Anemia
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins212016-09-012022-07-12
Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.
Extracorporeal Photopheresis Procedure (FEC) - Liver Transplantation, Immunosuppression
Phase 1 / Phase 2CompletedRed de Terapia Celular102013-04-012017-03-30
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
Immunosuppression withdrawal - Liver Transplant Recipients, Liver Transplantation
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1612012-08-142019-10-07
TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs
TBE-vaccine, Vaccination against TBE - Rheumatoid Arthritis, Exposed to TBE-virus
Phase 2CompletedSormland County Council, Sweden682010-05-012011-05-25
Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients
inactivated non adjuvanted pandemic H1N1 vaccine - Renal Transplant Recipients, Immunosuppression
Phase 2CompletedInstitut National de la Santé Et de la Recherche Médicale, France1222009-11-012026-02-19
Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention
Dietary intervention - supplements - Immunosuppression, Hyperlipidemias
Phase 1 / Phase 2CompletedUniversity of Alberta462005-11-012009-07-28
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Daclizumab - Anterior Uveitis, Arthritis, Juvenile Idiopathic
Phase 2CompletedNational Eye Institute (NEI)62005-08-012017-01-30
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
Alemtuzumab, Tacrolimus, Mycophenolate mofetil - Kidney Failure, Chronic, Kidney Transplantation
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)352005-01-012017-01-02
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
SOLEX 300i Stem Cell Selection - Immunosuppression, Leukemia
Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)702002-01-232019-12-16

Narrower conditions

Anemia, Aplastic (1)  ·  Arthritis, Juvenile (1)  ·  Arthritis, Rheumatoid (1)  ·  Bone Marrow Failure Disorders (1)  ·  COVID-19 (1)  ·  Diabetes Mellitus, Type 1 (1)  ·  Graft vs Host Disease (1)  ·  Hyperlipidemias (1)  ·  Iritis (1)  ·  Kidney Failure, Chronic (1)  ·  Leukemia (1)  ·  Neoplasms, Plasma Cell (1)  ·  Renal Insufficiency (1)  ·  Uveitis, Anterior (1)

Broader conditions

Immune System Diseases (4)  ·  Autoimmune Diseases (3)  ·  Arthritis (2)  ·  Connective Tissue Diseases (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Joint Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Rheumatic Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Anemia (1)  ·  Bone Marrow Diseases (1)  ·  Chronic Disease (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)

Interventions

Mycophenolic Acid (2)  ·  Tacrolimus (2)  ·  Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Cyclophosphamide (1)  ·  Daclizumab (1)  ·  FEC protocol (1)  ·  NVX-CoV2373 adjuvated lipid nanoparticle (1)  ·  Sirolimus (1)  ·  Whole-Body Irradiation (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)  ·  thymoglobulin (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)  ·  National Eye Institute (NEI) (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Red de Terapia Celular (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  Sormland County Council, Sweden (1)  ·  University of Alberta (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (6)  ·  Canada (2)  ·  Finland (1)  ·  France (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

A. John Barrett, M.D. (1)  ·  Amy E DeZern, MD (1)  ·  Freddy Caldera, DO, MS (1)  ·  J Bucuvalas, M.D. (1)  ·  Lars Rombo, MD Professor (1)  ·  Michael T Clandinin, PhD (1)  ·  S Feng, M.D., Ph.D. (1)  ·  William Harmon, MD (1)

Results publications

PMID 19664754, PMID 22052056, PMID 23065508, PMID 23103195, PMID 23524640, PMID 32343796, PMID 32786149, PMID 33280227, PMID 35819312, PMID 37084383

NIH funding

2009 (1), U01AI100807 (1)